In <i>MYCN</i> amplified cell lines, the combination of radiation and an AURKA A inhibitor increased DNA damage and apoptosis and decreased MYCN protein levels.<h4>Conclusion</h4>The combination of AURKA inhibition with <sup>131</sup>I-MIBG treatment is active in resistant neuroblastoma models and is a promising clinical approach in high-risk neuroblastoma. This evidence concerns the gene AURKA and neuroblastoma.